Short-term variations in bone remodeling biochemical markers: Cyclical etidronate and alendronate effects compared

Journal of Clinical Endocrinology and Metabolism

Volumn 82, Issue 9, 1997, Pages 3034-3039

  Bettica, P ^a   Bevilacqua, M ^a   Vago, T ^a   Masino, M ^b   Cucinotta, E ^b   Norbiato, G ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b USSL 44   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ALKALINE PHOSPHATASE; BIOCHEMICAL MARKER; CALCIUM CARBONATE; COLLAGEN TYPE 1; DEOXYPYRIDINOLINE; ETIDRONIC ACID; OSTEOCALCIN;

ADULT; ARTICLE; BONE DENSITY; BONE MINERALIZATION; BONE REMODELING; BONE TURNOVER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; HUMAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; ORAL DRUG ADMINISTRATION; OSTEOLYSIS; OSTEOPOROSIS; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; URINARY EXCRETION;

EID: 0030953396     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jcem.82.9.4193     Document Type: Article

References (24)

1. Calvo MS, Eyre DR, Gundberg CM. 1996 Molecular basis and clinical application of biological markers of bone turnover. Endocr Rev. 17:333-368.
2. Seibel MJ, Robins SP, Bilezikian JP. 1992 Urinary pyridinium crosslinks of collagen: specific markers of bone resorption in metabolic bone disease. Trends Endocrinol Metab. 3:263-270.
3. Hanson DA, Weis MAE, Bollen AM, Maslan SL, Singer FR, Eyre DR. 1992 A specific immunoassay for monitoring human bone resorption: quantitation of type I collagen cross-linked N-telopeptides in urine. J Bone Miner Res. 7:1251-1258.
4. Garnero P, Ginetys E, Riou JP, Delmas PD. 1994 Assessment of bone resorption with a new marker of collagen degradation in patients with metabolic bone disease. J Clin Endocrinol Metab. 79:780-785.
5. Price PA, Otsuka AS, Poser JW, Kristaponis J, Raman N. 1976 Characterization of a gamma-carboxyglutamic acid-containing protein from bone. Proc Natl Acad Sci USA. 73:1447-1451.
6. Price PA, Parthemore JG, Deftos LJ. 1980 New biochemical marker for bone metabolism: measurement by radioimmunoassay for Gla protein in the plasma of normal subjects and patients with bone disease. J Clin Invest. 66:878-883.
7. Pastoreau P, Delmas PD. 1990 Measurement of serum bone Gla-protein (BGP) in humans with ovine BCP-based radioimmunoassay. Clin Chem. 36:1620-1624.
8. Taylor AK, Linkhart SG, Mohan S, Baylink DJ 1988 Development of a new radioimmunoassay for osteocalcin: evidence for a midmolecule epitope. Metabolism. 37:872-877.
9. Sergeant LE, Stinson RA. 1979 Evidence that three structural genes code for human alkaline phosphatase. Nature. 281:152-154.
10. Baileys EM, Newby AC, Siddle K, Luzio JP. 1982 Solubilization and purification of rat liver 5′-nucleotidase by use of a zwitterionic detergent and a monoclonal antibody immunoabsorbent. Biochem J. 203:245-251.
11. Stein GS, Lian JB, Owen TA. 1990 Relationship of cell growth to the regulation of tissue-specific gene expression during osteoblast differentiation. FASEB J. 4:3111-3123.
12. Fleisch H. 1981 Diphosphonates: history and mechanisms of action. Metab Bone Dis. 4/5:279-299.
13. Fleisch H, Russell RGG, Francis MD. 1969 Diphosphonates inhibit hydroxyapatite dissolution in vitro and bone resoprtion in vivo. Science. 165:1262-1264.
14. Eyre DR, Koob TJ, Van Ness KP. 1984 Quantification of hydroxypyridmium cross-links in collagen by high performance liquid chromatography. Anal Biochem. 137:380-388.
15. Garnero P, Ginetys E, Arbault P, Christiansen C, Delmas PD. 1995 Different effects of bisphosphonate and estrogen therapy on free and peptide-bound bone cross-links excretion. J Bone Miner Res. 10:641-649.
16. Garnero P, Shih WJ, Ginetys E, Karpf DB, Delmas P. 1994 Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab. 79:1693-1700.
17. Harris ST, Gertz BJ, Genant HK, et al. 1993 The effect of short term treatment with alendronate on vertebral density and biochemical markers of bone remodeling in early postmenopausal women. J Clin Endocrinol Metab. 76:1399-1406.
18. Adami S, Passeri M, Ortolani S, et al. 1995 Effects of oral alendronate and intranasal salmon calcitonin on bone mass and biochemical markers of bone turnover in postmenopausal women with osteoprosis. Bone. 17:383-390.
19. Chesnut CHI, McClung MR, Ensrud KE, et al. 1995 Alendronate treatment of the postmenopausal osteoporotic woman: effect of multiple dosages on bone mass and bone remodeling. Am J Med. 99:144-152.
20. Rodan GA, Seedor JG, Balena R 1993 Preclinical pharmacology of alendronate. Osteoporos Int. 3(Suppl 3):S7-S12.
21. Siris E, Weinstein RS, Altman R, et al. 1996 Comparative study of alendronate versus etidronate for the treatment of Paget's disease of bone. J Clin Endocrinol Metab. 81:961-967.
22. Bettica P, Moro L, Robins S, et al. 1992 Bone resorption markers: galactosyl hydroxylysine, pyridinium crosslinks, hydroxyproline compared. Clin Chem. 38:2313-2318.
23. Bettica P, Taylor AK, Talbot J, Moro L, Talamini R, Baylink J. 1996 Clinical performances of galactosyl hydroxylysine, pyridinoline and deoxypyridinoline in postmenopausal osteoporosis. J Clin Endocrinol Metab. 81:542-546.
24. Bettica P, Masino M, Cucinotta E, et al. 1997 Comparison of the clinical performances of the immunoenzimometric assays for N-terminal and C-terminal type 1 collagen telopeptides and the HPLC assay for pyridinium crosslinks. Eur J Clin Chem Clin Biochem. 35:63-68.